|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Abacavir-Lamivudine | EPZICOM**(tablet)** | Non-antineoplastic | Minimum | Low6 | Low3,7 | FDA Pregnancy Category C; malignant tumors observed in mice and rats; genotoxic in in vivo micronucleus test. |
| Minimum |
| Abacavir-Lamivudine-Zidovudine  | TRIZIVIR**(tablet)** | Non-antineoplastic | Minimum | Low6 | Low3,7 | FDA Pregnancy Category C; malignant tumors observed in mice and rats; genotoxic in in vivo micronucleus test. |
| Minimum |
| Abiraterone | Zytiga **(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split | Minimum | FDA Pregnancy Category X. Based on the mechanism of action, abiraterone may cause fetal harm or fetal loss if administered during pregnancy (note-only indicated for men with prostate cancer). Abiraterone is not indicated for use in women and is specifically contraindicated in women who are or may become pregnant. |
| Acitretin | Soriatane**(capsule)** | Reproductive Risk | Minimum | Do not open capsuleSwallow capsule whole | Minimum | Black Box warning on adverse reproductive effects; FDA Pregnancy Category X. |
| Ado-trastuzumab | Kadcyla**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | Conjugated monoclonal antibody; FDA Pregnancy Category D. When Compounding use a BSC or CACI. Recommended to use of CSTD during any step of handling. |
| Afatinib | Gilortif**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split Swallow tablet whole | Minimum | FDA Pregnancy Category D Based on findings from animal studies and its mechanism of action, GILOTRIF can cause fetal harm when administered to a pregnant woman. Special warnings on contraception for females while taking and 2 weeks post-treatment. |
| Anastrozole | Arimidex**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Low3,7 | FDA Pregnancy Category X. Disruption of estrogen dependent events during pregnancy.  |
| Minimum if unaltered tab |
|  Arsenic Trioxide | **Trisenox****(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | \*\*IARC Group 1 carcinogen. FDA Pregnancy Category D.When compounding use a BSC or CACI. Recommended to use of CSTD during any step of handling. |
| AzaCITIDine | Vidaza**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | \*\*IARC Group 2A carcinogen; FDA Pregnancy Category DWhen compounding use a BSC or CACI. Recommended to use of CSTD during any step of handling. |
| AzaTHIOprine | Imuran**(tablet)** | Non-Antineoplastic | Minimum | Low6 | Low3,7 | \*\*IARC Group 1 carcinogen; FDA Pregnancy Category D. |
| Minimum if unaltered tab |
| AzaTHIOprine | Imuran **(compounded Suspension)** | Non-Antineoplastic | Moderate1,4,6 | N/A | Low3,7 | \*\*IARC Group 1 carcinogen; FDA Pregnancy Category D. |
| Bacillus Calmette-Guerin (BCG) | Tice (BCG)**(bladder irrigation)** | Antineoplastic | High4,6 | N/A | High2,5,9 | **BCG contains live, attenuated mycobacteria**. Because of the potential risk for transmission BCG should be prepared with aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptables in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves, and a gown should be worn to avoid inhalation or contact with BCG organisms. FDA Pregnancy Category C. **When delivering to unit where it will be used take a bottle of bleach with the product in case of spills for neutralizing purposes.** |
| Bendamustine | Treanda**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. No reports describing it’s use during pregnancy however, other agents in this class are known to cause human teratogenicity. |
| Bicalutamide | Casodex**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 |  Low3,7 | FDA Pregnancy Category X. Androgen receptor inhibition during pregnancy may affect fetal development. |
| Minimum if unaltered tab |
| Bleomycin | Blenoxane **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2B; FDA Pregnancy Category D. Bleomycin caused developmental toxicity (teratogenicity or death) in two animal species, but there are no reports describing the use of the drug during the 1st trimester in humans.**\*Wear PPE when handling patient urine for 3 days after administration.** |
| Bortezomib | Velcade **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. No reports describing the use of bortezomib in human pregnancy have been located. The drug caused developmental toxicity at a dose one-half of the human clinical dose (HCD) in one of two species. |
| Bosutinib | Bosulif**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 |  Low3,7 | FDA Pregnancy Category D. The manufacturer warns that the drug can cause fetal harm based on the drug's mechanism of action. |
| Minimum if unaltered tab |
| Brentuximab vedotin | Adcetris **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | Conjugated monoclonal antibody; FDA Pregnancy Category D. No reports in human pregnancy have been located however, the mechanism of action suggests that the drug can cause fetal harm. **\*Wear PPE when handling patient urine or feces for 7 days after administration.** |
| Cabazitaxel | Jevtana **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. Adverse events have been observed in animal reproduction studies. Cabazitaxel is not indicated for use in women. May cause fetal harm if administered during pregnancy. |
|   |  |  |  |  |  |  |
| Cabergoline | Dostinex **(tablet)** | Reproductive Risk | Do not place in automated counting or packaging machines | Low6-Only if reproductive risk, if not minimum | Minimum | Inhibition of conception and embryo fetal effects at doses below recommended human dose; FDA Pregnancy Category B. |
| Low7- Only if reproductive risk, if not minimum |
| Capecitabine | Xeloda **(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Tablets should not be cut or crushed. | Minimum | Metabolized to fluorouracil; FDA Pregnancy category D. **\*\*\*Note: Fluorouracil is volatile. \*Wear PPE when handling patient urine for days and feces for 5 days.** |
| CarBAMazepine | TEGretol**(tablet, XR)** | Non-antineoplastic | Minimum | Low6 | Low3,7 | Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Category D. |
| Do not cut/crush/split extended release | Minimum if unaltered regular release tab |
| CarBAMazepine | TEGretol**(suspension)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Category D. |
| Carboplatin | Paraplatin**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnantwomen. \***Wear PPE when handling patient urine for 2 days after administration.** |
| Carfilzomib | Kyprolis**(injection)** |  Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. The manufacturer states that the drug can cause fetal harm based on its mechanism of action and findings in animals. Special warnings on contraception while taking and 2 weeks post-treatment. |
| Carmustine | BiCNU**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2A carcinogen; FDA Pregnancy Category D. Carmustine should be considered a potential teratogen if used during the period of organogenesis. Therefore, a woman whose condition requires treatment during organogenesis. **Note: Carmustine is volatile. \*Also, wear PPE when handling patient urine for 4 days after administration.** |
| Carmustine | BiCNU**(wafer)** | Antineoplastic | Do not place in automated counting or packaging machines | N/A | High9-placed during surgical procedure | IARC Group 2A carcinogen; FDA Pregnancy Category D. Carmustine should be considered a potential teratogen if used during the period of organogenesis. Therefore, a woman whose condition requires treatment during organogenesis. \*\*\***Note: Carmustine is volatile.** \***Wear PPE when handling patient urine for 4 days after administration.** |
| Chlorambucil | Leukeran **(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Tablet should be swallowed whole. Do not cut or crush. | Minimum | IARC Group 1 carcinogen; Pregnancy Category D. |
| Choriogonadotropin | Ovidrel**(SQ injection)** | Reproductive Risks | Minimum | N/A | Low3,7 If reproductive risk, minimum if not. | FDA pregnancy Category X. May cause fetal harm when administered to a pregnant woman. |
| Cidofovir | Vistide **(injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category C. Because of the lack of human data, the risk to the human embryo and fetus cannot be assessed. |
| CISplatin | Platinol**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2A carcinogen; FDA Pregnancy Category D.The drug is teratogenic and embryotoxic in two animal species. Because of the potential for embryo toxicity, the drug should be avoided during the 1st trimester. **\*\*\*Note: Cisplatin is volatile.** \***Wear PPE when handling patient urine for 7 days after administration.** |
| Cladribine | Leustatin**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. |
| Clobazam **(not on current NIOSH 2016 list)** | Onfi **(tablet)**  | Reproductive Risk | Minimum | Low6 | Minimum | Reproductive toxicity and Teratogenicity or other developmental toxicity: embryo-fetal mortality and other harm at low doses in rats and rabbits, present in human breast milk. |
| Onfi**(oral suspension)** | Moderate1,4,6-Only if reproductive risk, if not minimum | N/A | Low3,7-Only if reproductive risk, if not minimum |
| Clofarabine | Clolar**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. |
| ClonazePAM | Klonopin**(tablet)** | Reproductive Risks | Minimum | Low6 | Minimum | FDA Pregnancy Category D. Increased risk of congenital abnormalities when taken in first trimester. |
| Low3,7 |
| ClonazePAM | Klonopin**(compounded Suspension)** | Reproductive Risks | Moderate1,4,6-Only if reproductive risk, if not minimum | N/A | Low3,7-Only if reproductive risk, if not minimum | FDA Pregnancy Category D. Increased risk of congenital abnormalities when taken in first trimester. |
| Colchicine | Colcrys**(tablet)**Mitigare **(capsule)** | Reproductive Risks | Minimum | Low6 | Minimum | FDA Pregnancy Category C. Published animal reproduction and development studies indicate it causes embryo-fetal toxicity, teratogenicity, and altered postnatal development at exposures within or above the clinical therapeutic range. |
| Low7 |
| Cyclophosphamide | Cytoxan**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Not recommended to crush or divide tablets | Low3,7 | IARC Group 1 carcinogen; FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 5 days after administration.** |
| High3,6 | Minimum if unaltered tab |
| Cyclophosphamide | Cytoxan**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 1 carcinogen; FDA Pregnancy Category D. \*\*\*Note: Cyclophosphamide is volatile. **\*Wear PPE when handling patient urine and feces for 5 days days after administration.** |
| Cyclosporine | Neoral, Gengraf, SandIMMUNE **(capsule)** | Non-antineoplastic | Minimum | Not recommended to open capsule. | Low3,7If capsule opened. | IARC Group 1 carcinogen; FDA Pregnancy Category C. |
| High3,6 | Minimum if unaltered capsule. |
| Cyclosporine | Neoral, Gengraf, SandIMMUNE**(injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 1 carcinogen; FDA Pregnancy Category C. |
| Cyclosporine | Restasis**(ophthalmic)** | Non-antineoplastic | Minimum | N/A | Low3,7 | IARC Group 1 carcinogen; FDA Pregnancy Category C. |
| Cyclosporine | Neoral,Gengraf**(oral solution)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 |  |
| Cytarabine | Cytosar **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 1 day after administration.** |
| Dacarbazine | DTIC **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2B carcinogen. FDA Pregnancy Category C. \***Wear PPE when handling patient urine for 1 day after administration.** |
| DACTINomycin | Cosmegen **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. |
| Dasatinib | Sprycel **(tablets)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not be cut or crush tablet. | Minimum | FDA Pregnancy Category D. |
| Daunorubicin | Cerubidine**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2B, AKA daunomycin; FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 7 days and feces for 7 days after administration.** |
| Decitabine | Dacogen **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. |
| Degarelix | Firmagon **(SQ injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7 | FDA Pregnancy Category X.  |
| Dexrazoxane | Zinecard**(injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category C; secondary malignancies observed in patients treated long term with Razoxane (a racemic mixture containing dexrazoxane); Genotoxic in vitro and in vivo; In laboratory studies, testicular atrophy observed at or below the human dose. |
| Dinoprostone | Cervidil, Prostin E2 **(vaginal insert, supp)** | ReproductiveRisks | Minimum | N/A | Low7 | FDA Pregnancy Category X. Hazardous only for women in late pregnancy. |
| Divalproex sodium | Depakote**(tab ER, tab EC, cap sprinkle)** | Non-antineoplastic | Minimum | Do Not Cut/Crush/Split Enteric Coated or Extended Release Tablets | Minimum | FDA Pregnancy Category D. Tumors seen in laboratory studies at dose below maximum recommended human dose. Black Box warning for teratogenicity. |
| Low7-if opening capsule |
| DOCEtaxel | Taxotere **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine and feces for 7 days after administration.** |
| DOXOrubicin | Adriamycin**(injection, TACE Beads)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 2A Carcinogen; FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 6 days and feces for 7 days after administration.** |
| Doxorubicin Lipid | Doxil**(injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | IARC Group 2A Carcinogen; FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 6 days and feces for 7 days after administration.** |
| Dronedarone | Multaq**(tablet)** | Reproductive Risks | Minimum | Not recommended to cut/crush/split | Minimum | Teratogenic in laboratory studies at ½ MRHD; FDA Pregnancy Category C. |
| Low6 | Low7 |
| Dutasteride | Avadart**(capsule)** | ReproductiveRisks | Minimum | Do not open capsule | Minimum | Women warned not to handle; FDA Pregnancy Category X.If pregnant woman or woman of childbearing potential comes in contact with leaking capsules, the contact area should be washed immediately with soap and water. |
| EpiRUBicin | Ellence**(injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine and feces for 3 days after administration.** |
| EriBULin | Halaven**(injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. **\*Wear PPE when handling patient urine and feces for greater than 40 hours.** |
| Eroltinib | Tarceva**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Not recommended to crush | Minimum | FDA Pregnancy Category D. |
| Low6 | Low7 |
| Eslicarbazepine **(not currently listed in 2016 NIOSH)** | Aptiom **(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | Metabolized to Oxcarbazepine. FDA Pregnancy Category C; The dose not associated with an increase in tumors(100 mg/kg/day) is less than the MRHD (1600 mg/day for monotherapy)on a mg/m2 basis. |
| Low3,7 |
| Estradiol, Estropipate**(tablets, topical)** | Estrace, Climara, Ogen | Non-antineoplastic | Minimum | Not recommended to cut/crush/split | Minimum | Black box warning for malignant neoplasms; increased risk of endometrial cancer, breast cancer, and ovarian cancer; in laboratory studies, increased frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver; present in breast milk; FDA Pregnancy Category X. |
| Low6 | Low7 -topical |
| Estrogens**(cream,tablet,patch)** | multiple | Non-antineoplastic | Minimum | Do not cut/crush/split | Minimum | Black Box warning for endometrial cancer and cardiovascular risks; long-term use in women and laboratory studies increases frequency of several cancers; FDA Pregnancy Category X. |
| Low7-topical |
| Estrogens-Methyltest  | Estratest**(tablet)** | Non-antineoplastic | Minimum | Not recommended to cut/crush/split | Minimum | Estrogen-Black Box warning for endometrial cancer and cardiovascular risks; long-term use in women and laboratory studies increases frequency of several cancers; FDA Pregnancy Category X. |
| Low6 | Low7 |
| Etoposide | Vepesid**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not break or open capsule. | Minimum | IARC Group 1 carcinogen; FDA Pregnancy Category D. \***Wear PPE when handling patient urine and feces for 5 days after administration.** |
| Etoposide | Vepesid **(injection)** | High4,6 | N/A | Moderate3,7,8 | IARC Group 1 carcinogen; FDA Pregnancy Category D. . \*\*\*Note: Etoposide is volatile.\***Wear PPE when handling patient urine and feces for 5 days after administration.** |
| Etoposide Phosphate | Etopophos**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | IARC Group 1 carcinogen; FDA Pregnancy Category D. . \*\*\*Note: Etoposide is volatile.\***Wear PPE when handling patient urine and feces for 5 days after administration.** |
| Everolimus | Afinitor**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split tablet. | Minimum | FDA Pregnancy Category D. |
| Finasteride | Proscar**(tablet)** | ReproductiveRisks | Minimum | Not recommended to cut/crush/split. | Minimum | \Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant due to potential risk to a male fetus; FDA Pregnancy Category X. |
| Low6 | Low7 |
| Fingolimod | Gilenya**(capsule)** | Non-antineoplastic | Minimum | Do not open capsule.  | Minimum | FDA Pregnancy Category C; In laboratory studies, increased malformations and embryo-fetal deaths at less than the RHD; malignant lymphomas observed in male and female mice. |
| Fluconazole | Diflucan**(tablet)** | ReproductiveRisks | Minimum | Low6-Only if reproductive risk, if not minimum | Minimum | FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400-800 mg/day) during most or all of the first trimester, similar to those seen in animal studies. |
| Low7-Only if reproductive risk, if not minimum |
| Fluconazole | Diflucan **(Suspension)** | ReproductiveRisks | Moderate1,4,6-Only if reproductive risk, if not minimum | N/A | Low3,7-Only if reproductive risk, if not minimum | FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400-800 mg/day) during most or all of the first trimester, similar to those seen in animal studies. |
| Fluconazole | Diflucan**(injection)** | ReproductiveRisks | High4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7,8 -Only if reproductive risk, if not minimum | FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400-800 mg/day) during most or all of the first trimester, similar to those seen in animal studies. |
| Fludarabine | Fludara**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 3 days after administration.** |
| Fluorouracil | Adrucil**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. **\*\*\*Note: Fluorouracil is volatile. \*Wear PPE when handling patient urine for 2 days and feces for 5 days after administration.** |
| Fluorouracil | Efudex**(cream)** | Minimum | N/A | Low3 | Wear Chemo Rated gloves. FDA Pregnancy Category D.  |
| Flutamide | Eulexin**(capsule)** | Antineoplastic  | Do not place in automated counting or packaging machines | Not recommended to open capsule. | Minimum | FDA Pregnancy Category D. Carcinogenic in rats. Indicated only for men. |
| Low6 | Low3,7 |
| Fosphenytoin | Cerebyx**(injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | Metabolized to phenytoin; FDA Pregnancy Category D.  |
| Fulvestrant | Faslodex**(IM injection)** | Antineoplastic | Minimum | N/A | Moderate3,7 | FDA Pregnancy Category D.  |
| Ganciclovir | Cytovene**(injection)** | Non--antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category C. **\*Wear PPE when handling patient urine for 2 days after administration.** |
| Gemcitabine | Gemzar**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 7 day after administration.** |
| Goserelin | Zoladex**(SQ injection)** | Antineoplastic | Minimum | N/A | Moderate3,7 | FDA Pregnancy Category X.  |
| Hydroxyurea | Hydrea**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do Not Open Capsules | Minimum | FDA Pregnancy Category D; Special warning on handling bottles and capsules-“Wash hands with soap and water before and after contact with the bottle or capsules when handling HYDREA. Do not open HYDREA capsules. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be flushed thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water.” |
| Hydroxyurea | Hydrea**(compounded suspension)** | Antineoplastic | Moderate1,4,6 | N/A | Moderate3,7 | FDA Pregnancy Category D; Special warning on handling bottles and capsules-“Wash hands with soap and water before and after contact with the bottle or capsules when handling HYDREA. Do not open HYDREA capsules. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be flushed thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water.” |
| IDArubicin | Idamycin**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 3 days and feces for 2 days after administration.** |
| Ifosfamide | Ifex**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. **\*\*\*Note: Ifosfamide is volatile.** \***Also,** **wear PPE when handling patient urine for 2 days after administration.** |
| Imatinib | Gleevec**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | N/A | Minimum | FDA Pregnancy Category D. \***Wear PPE when handling patient urine and feces for 7 days after administration.** |
| Moderate3,7 if dissolved in water or apple juice |
| Inotuzumab ozogamicin **(not on current NIOSH 2016)** | Besponsa **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. |
| Irinotecan | Camptosar**(injection, TACE Beads)** |  Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. |
| Ixabepilone | Ixempra**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. Not teratogenic but did cause embryo-fetal toxicity. \***Wear PPE when handling patient urine and feces for 7 days after administration.** |
| Ixazomib | Ninlaro**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not crush or open capsule | Minimum | Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment. |
| Leflunomide | Arava**(tablet)** | Non-antineoplastic | Minimum | Not recommended to cut or crush. | Minimum | FDA Pregnancy Category X; Teratogenic in laboratory studies at 1/10 human dose (HD); marked postnatal survival at 1/100 HD; severe liver injury reported in patients; carcinogenicity observed at doses below HD. |
| Low6 | Low3,7 |
| Lenalidomide | Revlimid**(capsule)** | Non-antineoplastic | Minimum | Capsules should not be opened or broken. | Minimum | FDA Pregnancy Category X; Analog of thalidomide; Black Box warnings for limb abnormalities; in laboratory studies, caused thalidomide-type limb defects in monekey offspring. |
| Letrozole | Femara **(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Not recommended to crush, cut, or split. | Minimum | FDA Pregnancy Category X |
| Leuprolide acetate | LupronEligard**(IM, SQ injection)** | Antineoplastic | High4,6-If prepared from vial. | N/A | Moderate3,7-If in ready to administer syringe | FDA Pregnancy Category X |
| High3,4,7-if drawn up from vial |
| Liraglutide | Victoza**(SQ injection)** | Non-antineoplastic | Minimum | N/A | Moderate3,7 | FDA Pregnancy Category C; Black Box warning for thyroid C-cell tumors, with supporting evidence in laboratory studies; also in laboratory studies, teratogenic at or below the MRHD. |
| Mechlorethamine | Mustargen**(injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D; National Toxicology Program-Known to be human carcinogen. **\*\*\*Note: Mechlorethamine is volatile.**  |
| MedroxyPROGESTERone | Provera**(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | FDA Pregnancy Category X; IARC Group 2B.. |
| Low3,7 |
| MedroxyPROGESTERone  | Depo-Provera**(IM/SQ injection)** | High4,6 | N/A | High3,7-If from vial |
| Moderate3,7-If ready to administer manufacturer syringe or SQ system. |
| Megestrol | Megace **(tablet)** | Antineoplastic  | Do not place in automated counting or packaging machines | Low6 | Minimum | FDA Pregnancy Category X; Nursing should be discontinued if megestrol is required; women at risk of pregnancy should avoid exposure. |
| Low3,7 |
| Megestrol | Megace**(suspension)** | Antineoplastic | Moderate1,4,6 | N/A | Moderate3,7 | FDA Pregnancy Category X; Nursing should be discontinued if megestrol is required; women at risk of pregnancy should avoid exposure. |
| Minimum if in unit dose cup |
| Melphalan | Alkeran**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Minimum | FDA Pregnancy Category D; IARC Group 1 carcinogen; National Toxicology Program-Reasonably Anticipated to be human carcinogen. \***Wear PPE when handling patient urine for 2 days and feces for 7 days after administration.** |
| Low3,7 |
| Melphalan | Alkeran**(injection)** | High4,6 | N/A | Moderate3,7,8 |
| Mercaptopurine | Purinethol**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Minimum | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 2 days and feces for 5 days after administration.** |
| Low3,7 |
| Mercaptopurine | Purinethol**(compounded suspension)** | Antineoplastic | Moderate1,4,6 | N/A | Moderate3,7 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 2 days and feces for 5 days after administration.** |
| Methimazole | Tapazole**(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | FDA Pregnancy Category D; Appears in human breast milk. |
| Low3,7 |
| Methotrexate | Folex**(Tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Minimum | FDA Pregnancy Category X. \***Wear PPE when handling patient urine for 3 days and feces for 7 days after administration.** |
| Low3,7 |
| Methotrexate | Folex**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category X. \***Wear PPE when handling patient urine for 3 days and feces for 7 days after administration.** |
| Methylergonovine | Methergine**(tablet)** | ReproductiveRisks | Minimum | Low6 | Minimum | FDA Pregnancy Category C; Use is contraindicated during pregnancy because of its uterotonic effects. |
| Low3,7 |
| Methylergonovine | Methergine **(injection)** | Minimum | N/A | High3,7 –if from ampule and if reproductive risk, minimum if not |
| Moderate3,7 –if from vial and reproductive risk, minimum if not. |
| MiSOPROStol | Cytotec**(tablet)** | ReproductiveRisks | Minimum | Low6 | Minimum | FDA Pregnancy Category X. |
| Low3,7 |
| MitoMYCIN C | Mutamycin**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D; IARC Group 2B. \***Wear PPE when handling patient urine and feces for 1 day after administration.** |
| MitoMYCIN C | Mutamycin **(Bladder instillation)** | High4,6 | N/A | High2,5,9 |
| MitoXANTRONE | Novantrone**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D; IARC Group 2B. \***Wear PPE when handling patient urine for 6 days and feces for 7 days after administration.** |
| Mycophenolate mofetil | Cellcept, Myfortic**(tablet, capsule)** | Non-antineoplastic | Minimum | Do not crush or cut tablet and do not open capsule. | Minimum | FDA Pregnancy Category C; Black Box warning for embryo fetal toxicity, malignancies, and serious infections; increase risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in capsules and oral suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. |
| Mycophenolate mofetil | Cellcept, Myfortic**(compoundedsuspension)** | Moderate1,4,6 | N/A | Low3,7 |
| Mycophenolate mofetil | Cellcept, Myfortic **(injection)** | High4,6 | N/A | Moderate3,7,8 |
| Nevirapine | Viramune**(suspension)** | Non-antineoplastic  | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category B; in laboratory studies, hepatocellular adenomas and carcinomas at doses lower than human dose. |
| Nilotinib | Tasigna**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not open capsule | Minimum | FDA Pregnancy Category D. May cause fetal harm. |
| Omacetaxine | Synribo**(SQ injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. May cause fetal harm.  |
| Ospemifene | Osphena **(tablet)** | Non-Antineoplastic | Minimum | No information on Crushing or Cutting tablet. | Minimum | Black Box warning on increased risk of endometrial cancer in certain populations; risk of adverse outcomes during pregnancy and labor; FDA Pregnancy Category X. |
| Oxaliplatin | Eloxatin**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D; \***Wear PPE when handling patient urine for 3 days after administration.** |
| OXcarbazepine | Trileptal**(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | FDA Pregnancy Category C; Tumors observed in laboratory studies a 1/10 MRHD. |
| Low3,7 |
| Oxcarbazepine | Trileptal**(suspension)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category C; Tumors observed in laboratory studies a 1/10 MRHD. |
| Oxytocin | Pitocin**(injection)** | Reproductive Risks | High4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7,8 -Only if reproductive risk, if not minimum | FDA Pregnancy Category C; **Hazardous only for women in 2nd and 3rd trimester.** |
| PACLitaxel | Taxol, Onxol**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 2 days and feces for 2 days after administration.** |
| PACLitaxel protein bound | Abraxane**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 2 days and feces for 2 days after administration.** |
| Palbociclib (n/a) | Ibrance**(tablet)** | Reproductive Risks | Minimum | Do not open capsules. | Minimum | FDA Pregnancy Category Unclassified. |
| Paliperidone | Invega**(tablet)** | Non-antineoplastic | Minimum | Do not crush/cut/split tablet | Minimum | FDA Pregnancy Category C; Metabolite of risperidone; excreted in human breast milk. |
| Invega Sustenna**(IM injection)** | Minimum | N/A | Moderate3,7 |
| Pamidronate | Aredia**(Injection)** | Reproductive Risks | High4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7,8 -Only if reproductive risk, if not minimum | FDA Pregnancy Category D; Embryo-fetal toxicities at doses below the recommended human dose. |
| Paroxetine | Paxil, Paxil CR**(tablet)** | Reproductive Risks | Minimum | Low6 | Minimum | FDA Pregnancy Category D; Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in third trimester. |
| Low3,7 |
| Do not cut/crush/split controlled release tablet | N/A |
| PAZOPanib | Votrient**(tablet)** | Antineoplastic  | Do not place in automated counting or packaging machines | Do not crush tablet | Minimum | FDA Pregnancy Category D. Hepatotoxicity |
| PEMEtrexed | Alimta**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D |
| Pentostatin | Nipent**(Injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D |
| Pertuzumab | Perjeta**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Preg­nancy Category D; Black Box warning on embryo-fetal death and birth defects. |
| Phenoxybenzamine | Dibenzyline**(Capsule)** | Non-antineoplastic | Minimum | If capsule opened Low6 | Minimum | Pregnancy Category C; IARC Group 2B. |
| Low3,7 |
| Phenytoin  | Dilantin **(suspension)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | Pregnancy Category D; IARC Group 2B; National Toxicology Program Reasonably Anticipated to be carcinogen. |
| Phenytoin | Dilantin **(injection)** | High4,6 | N/A | Moderate3,7,8 |
| Phenytoin | Dilantin**(Tablet, ER capsule)** | Minimum | Do not cut-crush-open extended release capsule | Minimum |
| Low6 | Low3,7 |
| Pomalidomide | Pomalyst**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Capsules should not be opened, broken, or chewed. | Minimum | FDA Pregnancy Category X; Females of reproductive potential must use two forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping treatment. |
| PRALAtrexate | Folotyn**(injection)** | Antineoplastic  | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D |
|  Procarbazine | Matulane**(capsule)** | Antineoplastic  | Do not place in automated counting or packaging machines | Not recommended to open capsule | Minimum | FDA Pregnancy Category D; IARC Group 2A carcinogen; National Toxicology Program-Reasonably Anticipated to be human carcinogen. \***Wear PPE when handling patient urine for 3 days after administration.** |
| Low6 | Low3,7 |
| Progesterone | Prometrium**(capsule)** | Non-antineoplastic | Minimum | Not recommended to open capsule | Minimum | IARC Group 2B; National Toxicology Program-Reasonably Anticipated to be human carcinogen. |
| Low6 | Low7 |
| Propylthiouracil | PTU**(tablet)** | Non-antineoplastic  | Minimum | Low6 | Minimum | Pregnancy Category D; IARC Group 2B; NTP-Reasonably Anticipated to be human carcinogen. |
| Low7 |
| Raloxifene | Evista**(tablet)** | Non-antineoplastic | Minimum | Do not break or crush tablet | Minimum | FDA Pregnancy Category X; Abortion and developmental abnormalities seen at low doses in laboratory studies; evidence of tumors at low doses in laboratory studies. |
| Rasagiline | Azilect**(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | FDA Pregnancy Category C. |
| Low7 |
| Ribociclib | Kisqali**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split/chew tablets | Minimum | Can cause fetal harm when administered to a pregnant women.  |
| Ribavirin | Rebetol **(capsule)**Copegus**(tablet)** | Reproductive Risk | Minimum | Do not crush, break tablet or open capsule. | Minimum | Teratogenic and embryotoxic effects in several laboratory studies; contraindicated in women who are pregnant and in the male partners of women who are pregnant; FDA Pregnancy Category X |
| Risperidone  | RisperDAL **(solution)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category C; Evidence of tumors at low doses in laboratory studies; may be prolactin-mediated. |
| Risperidone | RisperDAL M-Tab**(tablet)** | Minimum | Do not cut/crush/splitM-tablet | Minimum |
| Risperidone | RisperDAL**(tablet)** | Minimum | Low6 | Minimum |
| Low7 |
| Risperidone  | RisperDAL Constra **(IM injection)** | Minimum | N/A | Moderate3,7 |
| RomiDEPsin | Istodax**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D |
| Sirolimus | Rapamune**(tablet)** | Non-antineoplastic | Minimum | Do not cut/crush/split tablets | Minimum | FDA Pregnancy Category C; AKA rapamycin; increased risk of lymphomas and other malignancies; embryotoxic and fetotoxic at 0.2 human dose. |
| SORAfenib | NexAVAR**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split tablets | Minimum | FDA Pregnancy Category D. |
| Spironolactone | Aldactone**(tablet)** | Non-antineoplastic | Minimum | Low6 | Minimum | FDA Pregnancy Category C; Black Box warning for tumorogenicity in laboratory studies. |
| Low7 |
| Spironolactone | Carospir **(suspension)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category C; Black Box warning for tumorogenicity in laboratory studies. |
| Streptozocin | Zanosar**(Injectable)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. IARC Group 2B; National Toxicology Program-Reasonably Anticipated to be human carcinogen. |
| SUNitinib | Sutent**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do Not Open Capsule | Minimum | FDA Pregnancy Category D. |
| Tacrolimus | Prograf**(capsule)** | Non-antineoplastic | Minimum | Low6 | Minimum if unaltered | FDA Pregnancy Category C; Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk. |
| Low7 |
| Tacrolimus | Prograf **(compounded suspension)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category C; Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk. |
| Tacrolimus | Prograf **(solution)** | Non-antineoplastic | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category C; Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk. |
| Tacrolimus | Prograf**(Injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category C; Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk. |
| Tamoxifen | Nolvadex**(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Minimum if unaltered | FDA Pregnancy Category D; IARC Group 1 carcinogen; National Toxicology Program-Known to be human carcinogen. |
| Low7 |
| Telavancin(non-formulary) | Vibativ**(Injection)** | Reproductive Risks | High4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7,8 -Only if reproductive risk, if not minimum | FDA Pregnancy Category C. Black Box warning for potential risk to fetus and adverse reproductive outcomes; reduced fetal weights and increased rates of digit and limb malformations in three species at clinical doses. |
| Temazepam | Restoril**(capsule)** | Reproductive Risks | Minimum | Not Recommended to open capsule | Minimum | FDA Pregnancy Category X. Increased risk of congenital malformations associated with treatment during the first trimester of pregnancy. |
| Temozolomide | Temodar**(capsule)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not open capsules | Minimum | FDA Pregnancy Category D |
| Temozolomide | Temodar**(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D |
| Temsirolimus | Torisel**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine and feces for 14 days after administration.** |
| Teniposide | Vumon**(Injection)** | Antineoplastic | High 1,4 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. IARC Group 2A carcinogen. \***Wear PPE when handling patient urine for 5 days after administration.** |
| Testosterone | Depo-testosterone**(IM Injection)** | ReproductiveRisks | High4,6 only if reproductive risks, minimum if not | N/A | Moderate3,7 only if reproductive risks, minimum if not | FDA Pregnancy Category X. Children should avoid contact with unwashed or unclothed applications sites on skin (topical creams/gels). |
| Testosterone | Androgel**(Topical)** | Reproductive Risks | Minimum | N/A | Low-topical | FDA Pregnancy Category X. Children should avoid contact with unwashed or unclothed applications sites on skin (topical creams/gels). |
| Testosterone | Androderm**(Topical)** | Reproductive Risks | Minimum | N/A | Low-topical | FDA Pregnancy Category X. Children should avoid contact with unwashed or unclothed applications sites on skin (topical creams/gels). |
| Thalidomide | Thalomid**(Capsule)** | Non-antineoplastic | Minimum | Do not open, break or chew capsules | Minimum | FDA Pregnancy Category X. |
| Thioguanine | Tabloid **(tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Low6 | Minimum if unaltered | FDA Pregnancy Category D. |
| Low7 |
| Thiotepa | Thiotepa**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. IARC Group 1 carcinogen; National Toxicity Program-Known to be human carcinogen. \*\*\***Note: Thiotepa is volatile.** \***Wear PPE when handling patient urine for 3 days after administration.** |
| Thiotepa | Thiotepa**(Bladder Irrigation)** | Antineoplastic | High4,6 | N/A | High2,5 | FDA Pregnancy Category D. IARC Group 1 carcinogen; National Toxicity Program-Known to be human carcinogen. \*\*\***Note: Thiotepa is volatile.** \***Wear PPE when handling patient urine for 3 days after administration.** |
| Tofacitinib**(not on current NIOSH 2016 list)** | Xeljanz **(tablet, XR)** | Non-Antineoplastic | **Minimum** | Low6 | **Minimum if unaltered** | Lymphoma and other malignancies have been observed in patients treated with Tofacitinib. Available data with use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. |
| Do not cut/crush/split XR tablet. | Low7 |
| Topiramate | Topamax **(Sprinkle Capsule)** | Reproductive Risks | Minimum | N/A | Minimum if not opened | FDA Pregnancy Category D. |
| Low7 |
| Topiramate | Topamax **(Suspension)** | Reproductive Risks | Moderate1,4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7 only if reproductive risks, minimum if not | FDA Pregnancy Category D. |
| Topotecan | Hycamtin**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 2 days after administration.** |
| Trabectedin **(not currently on 2016 NIOSH list)** | Yondelis **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | Based on mechanism of action may cause fetal harm. May cause decreased fertility in males and females. |
| Tretinoin | Retin-A**(Capsule)** | Reproductive Risks | Minimum | Do not open capsule | Minimum | FDA Pregnancy Category X. Black box warning for severe birth defects; Special FDA distribution system. |
| Tretinoin | **(cream,gel)** | Minimum | N/A | Low-topical |
| Trifluridine/Tipiracil | Lonsurf**(Tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split | Minimum | Embryo-fetal lethality and embryo-fetal toxicity at doses lower than or similar to exposures at the recommended human dose. |
| Triptorelin | Trelstar LA**(IM Injection)** |  Antineoplastic | Minimum | N/A | High3,7 | FDA Pregnancy Category X |
| Ulipristal | Ella**(Tablet)** | ReproductiveRisks  | Minimum | Do not cut/crush/split | Minimum | FDA Pregnancy Category X |
| ValGANciclovir | Valcyte**(Solution)** | Non-antineoplastic | Moderate4,6 | N/A | Low3,7 | FDA Pregnancy Category C. |
| Valproic acid | Depakote**(Capsule)** | Reproductive Risks | Minimum | Do not cut/open/chew capsules | Minimum | FDA Pregnancy Category X (migraine prophylaxis)/D (all other indications). Black box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species. |
| Valproic acid | Depakote**(Solution)** | Reproductive Risks | Moderate1,4,6 | N/A | Low3,7 | FDA Pregnancy Category X (migraine prophylaxis)/D (all other indications). Black box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species. |
| Valproic acid | Depacon**(Injection)** | Reproductive Risk | High4,6 only if reproductive risks, minimum if not | N/A | Moderate3,7,8 only if reproductive risks, minimum if not | FDA Pregnancy Category X (migraine prophylaxis)/D (all other indications). Black box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species. |
| Valrubicin | Valstar **(Bladder Irrigation)** | Antineoplastic | High4,6 | N/A | High2,5,9 | FDA Pregnancy Category C |
| Vemurafenib | Zelboraf**(Tablet)** | Antineoplastic | Do not place in automated counting or packaging machines | Do not cut/crush/split  | Minimum | FDA Pregnancy Category D |
| VinBLAStine | Velban **(injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 4 days and feces for 7 days after administration.** |
| VinCRIStine | Vincasar**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 4 days and feces for 7 days after administration.**  |
| VinCRIStineliposomal | Marqibo**(Injection** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. **\*Wear PPE when handling patient urine for 4 days after administration**  |
| Vinorelbine | Navelbine**(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category D. \***Wear PPE when handling patient urine for 4 days and feces for 7 days after administration.** |
| Voriconazole | Vfend**(Injection)** | ReproductiveRisks | High4,6-Only if reproductive risk, if not minimum | N/A | Moderate3,7,8 -Only if reproductive risk, if not minimum | FDA Pregnancy Category D. Voriconazole was teratogenic and embryotoxic in animal studies.  |
| Voriconazole | Vfend**(Tablet)** | Reproductive risk | Minimum | Low6 – Only if reproductive risk, if not minimum | Minimum | FDA Pregnancy Category D. Voriconazole was teratogenic and embryotoxic in animal studies. |
| Low – Only if reproductive risk, if not minimum |
| Warfarin | Coumadin **(tablet)** | Reproductive Risks | Minimum | Low6 | Low3,7 | FDA Pregnancy Category D. Warfarin sodium tablets can cause fetal harm when administered to a pregnant woman. Warfarin sodium tablets exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. |
| Minimum if unaltered tablet Low3,7 |
| Zidovudine | Retrovir**(capsule)** | Non-antineoplastic | Minimum | Low6 | Low3,7 | FDA Preg­nancy Category C; IARC Group 2B. |
| Minimum |
| Zidovudine | Retrovir**(solution)** | Non-antineoplastic | Moderate4,6 | N/A | Low3,7 | FDA Preg­nancy Category C; IARC Group 2B. |
| Zidovudine | Retrovir **(Injection)** | Non-antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Preg­nancy Category C; IARC Group 2B. |
| Ziprasidone | Geodon **(Capsule)** | Reproductive Risks | Minimum | Low6 | Minimum if not altered | FDA Preg­nancy Category C. Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD. |
| Low7 |
| Ziprasidone | Geodon **(Compounded Suspension)** | Reproductive Risks | Moderate4,6 Only if reproductive risk, if not minimum | N/A | Moderate3,7 only if reproductive risks, minimum if not | FDA Preg­nancy Category C. Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD. |
| Ziprasidone | Geodon **(IM injection)** | Reproductive Risks | High4,6 only if reproductive risks, minimum if not | N/A | Moderate3,7 only if reproductive risks, minimum if not | FDA Preg­nancy Category C. Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD. |
| Ziv-aflibercept | Zaltrap **(Injection)** | Antineoplastic | High4,6 | N/A | Moderate3,7,8 | FDA Pregnancy Category C; Embryotoxic and teratogenic in rabbits at exposure levels lower than human exposures at the recommended dose, with increased incidences of external, visceral, and skeletal fetal malformations. |
| Zoledronic acid | Reclast, Zometa**(Injection)** | Reproductive Risks | High4,6 only if reproductive risks minimum if not | N/A | Moderate3,7,8 only if reproductive risks, minimum if not | FDA Pregnancy Category C. Number of stillbirths increased and survival of neonates decreased in laboratory studies at low doses. |
| Zonisamide | Zonegran**(Capsule)** | Reproductive Risks | Minimum | Not recommended to open capsule | Minimum if unaltered | FDA Preg­nancy Category C. Teratogenic in multiple miscellaneous animal species. |
| Low6 | Low3,7 |
| Zonisamide | Zonegran **(Compounded Suspension)** | Reproductive Risks | Moderate4,6 Only if reproductive risk, if not minimum | N/A | Moderate3,7 only if reproductive risks, minimum if not | FDA Preg­nancy Category C. Teratogenic in multiple miscellaneous animal species. |